Mallinckrodt (DB:MCD0) - Hisse Senedi Fiyatı, Haberler ve Analizler

MCD0 Stoklara Genel Bakış

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. Daha fazla detay

MCD0 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Risk Analizi

Negatif hissedar öz sermayesi

Anlamlı bir piyasa değeri yok ( €2M )

Hisse senetleri oldukça likit değildir

1 yıldan az nakit akışı var

Mallinckrodt plc Rakipler

Biofrontera

XTRA:B8FK

€15.8m

SynBiotic

DUSE:SBX

€27.9m

Cantourage Group

XTRA:HIGH

€57.9m

Apontis Pharma

XTRA:APPH

€81.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Mallinckrodt
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	€0.02
52 Haftanın En Yüksek Seviyesi	€7.35
52 Haftanın En Düşük Seviyesi	€0.02
Beta	0
11 Aylık Değişim	-97.74%
3 Aylık Değişim	-97.74%
1 Yıllık Değişim	n/a
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-99.73%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	MCD0	DE Pharmaceuticals	DE Pazar
7D	-74.4%	-0.3%	0.8%
1Y	n/a	-18.3%	8.6%

Getiri vs. Endüstri: MCD0 un German Pharmaceuticals sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Getiri vs Piyasa: MCD0 un German Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Fiyat Oynaklığı

Is MCD0's price volatile compared to industry and market?
MCD0 volatility
MCD0 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: MCD0 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: MCD0 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1867	2,687	Siggi Olafsson	www.mallinckrodt.com

Mallinckrodt plc Temel Bilgiler Özeti

Mallinckrodt'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MCD0 temel i̇stati̇sti̇kler
Piyasa değeri	€1.60m
Kazançlar(TTM)	-€2.74b
Gelir(TTM)	€1.74b

0.0x

P/S Oranı

0.0x

F/K Oranı

MCD0 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MCD0 gelir tablosu (TTM)
Gelir	US$1.89b
Gelir Maliyeti	US$1.25b
Brüt Kâr	US$640.60m
Diğer Giderler	US$3.61b
Kazançlar	-US$2.97b

Son Raporlanan Kazançlar

Sep 29, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-222.21
Brüt Marj	33.97%
Net Kâr Marjı	-157.55%
Borç/Özkaynak Oranı	-34.4%

MCD0 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

MCD0 Stoklara Genel Bakış

Risk Analizi

Mallinckrodt plc Rakipler

XTRA:B8FK

€15.8m

DUSE:SBX

€27.9m

XTRA:HIGH

€57.9m

XTRA:APPH

€81.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Mallinckrodt plc Presents Data on Terlipressin (Terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) At Kidney Week 2024

Mallinckrodt plc to Report Q3, 2024 Results on Nov 05, 2024

Mallinckrodt plc Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use®? Certification of Acthar®? Gel (repository Corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

CVC Capital Partners Fund IX managed by CVC Capital Partners plc (ENXTAM:CVC) entered into a definitive agreement to acquire Therakos business of Mallinckrodt from Mallinckrodt plc for approximately $925 million.

Mallinckrodt plc to Report Q2, 2024 Results on Aug 06, 2024

Recent updates

Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Mallinckrodt plc Presents Data on Terlipressin (Terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) At Kidney Week 2024

Mallinckrodt plc to Report Q3, 2024 Results on Nov 05, 2024

Mallinckrodt plc Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use®? Certification of Acthar®? Gel (repository Corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

CVC Capital Partners Fund IX managed by CVC Capital Partners plc (ENXTAM:CVC) entered into a definitive agreement to acquire Therakos business of Mallinckrodt from Mallinckrodt plc for approximately $925 million.

Mallinckrodt plc to Report Q2, 2024 Results on Aug 06, 2024

Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 European Association for the Study of the Liver (EASL) Congress

Mallinckrodt plc Reaffirms Financial Guidance for the Full Year of 2024

Mallinckrodt plc, Annual General Meeting, May 09, 2024

Mallinckrodt plc Provides Earnings Guidance for the Year 2024

Mallinckrodt Appoints Paul O'neill as Executive Vice President, Quality & Operations, Specialty Brands

Mallinckrodt plc Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® Mini-Cylinder

Mallinckrodt plc to Present Breadth of Data on Terlivaz (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome At the American Association for the Study of Liver Diseases (Aasld) 2023 Liver Meeting

Mallinckrodt plc Revises Earnings Guidance for the Full-Year of 2023

Mallinckrodt Presents Latest Health Economics Data on Acthar Gel (Repository Corticotropin Injection) At the Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar Gel (Repository Corticotropin Injection)

Mallinckrodt Reportedly Considers Sale of Opioid Business

Mallinckrodt plc Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)

Mallinckrodt plc(OTCPK:MNKT.Q) dropped from S&P TMI Index

NYSE American to Commence Delisting Proceedings Against Mallinckrodt

Mallinckrodt plc Filed for Bankruptcy

Mallinckrodt plc is Heading Towards Bankruptcy

Mallinckrodt plc Contemplates Bankruptcy

Second quarter 2023 earnings released

Mallinckrodt plc Reaffirms Sales Guidance for the Full-Year 2023

High number of new and inexperienced directors

Pomerantz LLP Announces That a Class Action Lawsuit Has Been Filed Against Mallinckrodt plc

Alta Fundamental Requests Mallinckrodt to Convene an Extraordinary General Meeting

Mallinckrodt to Present Data on Terlivaz® (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome

Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients

High number of new and inexperienced directors

Mallinckrodt plc Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023

Mallinckrodt plc Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released

High number of new and inexperienced directors

High number of new and inexperienced directors

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Mallinckrodt plc Temel Bilgiler Özeti

0.0x

0.0x

Kazanç ve Gelir